Powin Biomedical Co., Ltd.
Update：2025/01/01
Industries
Main Industry
Biotechnology
Main Product/Service
Challenges
Economic Losses:
The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.
Vaccine Hesitancy:
Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.
Evolving virus:
The threat posed by both the original and new variants of the virus continuously creates health concerns.
Opportunities
siRNA Innovation:
The FDA in the United States has approved several drugs for treating COVID-19, including antiviral medications, immune modulators, and renal replacement therapies.
IG-001, developed by Intelligene, is an siRNA drug that uses gene coding to combat the virus. We anticipate that IG-001 will provide precise targeted therapy for both known and potentially unknown variants.
IG-002
siRNA-based drug for universal flu treatment
Challenges
High Incidence and Severity:
Flu (Influenza) continues to be a significant public health challenge with an estimated 1 billion cases worldwide each year, including 3 to 5 million severe cases and hundreds of thousands of related respiratory deaths.
Emerging Pandemic Risk:
Recent lab tests with bird flu strains show that these viruses keep changing and can be a big health risk when they spread from animals to people. This warns us about possible big disease outbreaks or pandemics.
Opportunities
Advanced Drug Development:
IG-002 offers an opportunity for advanced gene therapy by targeting a conserved region in the virus' evolution, potentially addressing various flu strains.
Comprehensive and Precise Solution:
We expect IG-002 offer a more comprehensive and accurate nucleic acid therapeutic drugs with RNAi technology targeting specific genes and regions.
Economic Losses:
The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.
Vaccine Hesitancy:
Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.
Evolving virus:
The threat posed by both the original and new variants of the virus continuously creates health concerns.
Opportunities
siRNA Innovation:
The FDA in the United States has approved several drugs for treating COVID-19, including antiviral medications, immune modulators, and renal replacement therapies.
IG-001, developed by Intelligene, is an siRNA drug that uses gene coding to combat the virus. We anticipate that IG-001 will provide precise targeted therapy for both known and potentially unknown variants.
IG-002
siRNA-based drug for universal flu treatment
Challenges
High Incidence and Severity:
Flu (Influenza) continues to be a significant public health challenge with an estimated 1 billion cases worldwide each year, including 3 to 5 million severe cases and hundreds of thousands of related respiratory deaths.
Emerging Pandemic Risk:
Recent lab tests with bird flu strains show that these viruses keep changing and can be a big health risk when they spread from animals to people. This warns us about possible big disease outbreaks or pandemics.
Opportunities
Advanced Drug Development:
IG-002 offers an opportunity for advanced gene therapy by targeting a conserved region in the virus' evolution, potentially addressing various flu strains.
Comprehensive and Precise Solution:
We expect IG-002 offer a more comprehensive and accurate nucleic acid therapeutic drugs with RNAi technology targeting specific genes and regions.
Founded Year
2021
Unified Business No.
91044533
Status
Active
Number of Employees
0
Total Paid-in
Capital
40,500,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Taichung City
Website
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Intelligene stands as one of the pioneering drug development companies in Taiwan's biotechnology sector. We are at the forefront of advancing gene therapeutics through siRNA-based drugs, utilizing a revolutionary approach that harnesses the power of RNA interference technology to combat formidable adversaries. Our mission is to confront the looming threats of pandemics and influenza. Our dedicated team of scientists and researchers is united by a shared purpose: to safeguard and improve human well-being by developing innovative solutions. These solutions not only address the immediate challenges posed by infectious diseases but also hold the promise of a healthier future.
